Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01769547 |
| Title | A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy |
| Acronym | DOVE-M |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Ontario Clinical Oncology Group (OCOG)|Novartis Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | CAN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Tom Baker Cancer Centre | Calgary | Alberta | T2N 4N2 | Canada | Details | |
| Juravinski Cancer Centre | Hamilton | Ontario | L8V 5C2 | Canada | Details | |
| Ottawa General Hospital Cancer Centre | Ottawa | Ontario | K1H 8L6 | Canada | Details | |
| Northeast Cancer Centre, Health Sciences North | Sudbury | Ontario | P3E 5J1 | Canada | Details | |
| Princess Margaret Hospital | Toronto | Ontario | M5G 1X6 | Canada | Details |